Author: NewsEditor

Metro Atlanta’s Best Places to Work Determined by Employee Feedback collected by Energage

ATLANTA, March 20, 2023 (Newswire.com)
–
Digital Additive, an award-winning eCRM-focused agency specializing in Salesforce Marketing Cloud, is honored to be included as an award winner in Atlanta Journal-Constitution’s Metro Atlanta Top Workplaces 2023. This is the 12th year AJC has collaborated with employment research and consulting firm Energage to determine the best places to work in metro Atlanta.

A unique feature of the list is that it is based solely on employee feedback gathered by Energage through a confidential survey. This survey measures culture drivers critical to the success of any organization from alignment and connection to employee engagement and company leadership. Top workplaces are determined on how positively employees rate their workplaces, making it a genuine representation of the employee experience.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That’s something to be proud of. In today’s market, leaders must ensure they’re allowing employees to have a voice and be heard. That’s paramount. Top Workplaces do this, and it pays dividends.”

Earning this recognition reflects high organizational health. Research from Energage shows that the traits team members value most in the workplace are the core elements of overall organizational wellness. Additionally, companies with high organizational health typically outperform their peers in their industry.

“We’re really proud that Digital Additive has been included in this list. It shows in a measurable way that our commitment to building a supportive work environment is a lived experience by our teammates,” said Kevin Moran, Digital Additive CEO. “It will also ensure DA continues to attract and retain the best talent.”

About Digital Additive: 
In a world of one-size-fits-all communication, Digital Additive delivers on the promise of one-to-one. We don’t talk at people, we engage them in genuine conversations. Authentic connection, real relationships: that’s messaging done right. We get that. And it drives us every day, every send, to do it smarter than everyone else. Learn more and discover open positions at www.digitaladditive.com or contact Roxana Shershin at [email protected]. 

Contact Information:

Thrisa Powells

People Operations Director

[email protected]

4045515558 x 150

Original Source:

AJC Names Digital Additive to Top Workplaces 2023

The post AJC Names Digital Additive to Top Workplaces 2023 first appeared on Social Gov.

A new report examines the role of audio enhancement in education, healthcare and other applications.

NORTH CONWAY, …

The post Digitunity Report Identifies Need for Audio Enhancement first appeared on Social Gov.

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

LAS VEGAS, March 20, 2023 (Newswire.com)
–
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson’s disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences’ drug candidates. Gb Sciences’ first international patent also confirms that the Company’s intellectual property strategy can work globally and strengthens the Company’s patent portfolio. The global market for treatments of Parkinson’s disease is projected to grow to $8.8 billion by the year 2026, and new therapies to address Parkinson’s disease symptoms are greatly needed.

“The issuance of Gb Sciences’ first international patent protecting methods of using our proprietary cannabinoid-containing formulations for treating Parkinson’s disease is an important milestone in the development of these vitally important therapies. Gb Sciences’ recent patent issued in China validates both our plant-inspired drug discovery process and intellectual property strategy, which involve defining and protecting Minimum Essential Mixtures,” explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, Inc. “Gb Sciences starts its drug discovery process with plant-based therapies that are working anecdotally or in traditional medical systems, then we systematically reduce the number of compounds to reveal Minimum Essential Mixtures. Gb Sciences’ novel Minimum Essential Mixtures retain the increased efficacy of whole plant medicines, but they are easier to manufacture with precision at scale like single ingredient drugs. These Minimum Essential Mixtures are a viable alternative to standard single ingredient drugs or traditional whole plant medicines.”

Gb Sciences’ Minimum Essential Mixture-based drug development strategy does not aim to treat complex diseases as if they were caused by a single factor, but instead addresses the combination of factors that lead to a complex human disorder. Minimum Essential Mixtures (MEMs) are potentially more effective than single ingredient drugs because the different active ingredients target the multiple human processes responsible for complex diseases, such as neurodegeneration, heart disease, and cancers. As such, MEMs may offer a more holistic treatment for complex disorders such as Parkinson’s disease that cannot be attributed to a single cause, while maintaining the manufacturing and quality control advantages of single ingredient drugs.

Gb Sciences’ patent portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary plant-inspired therapies for more than 65 different disorders. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Alexis Quintal

[email protected]

Original Source:

GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China

The post GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China first appeared on Social Gov.